|Grant Number:||5R01CA149222-03 Interpret this number|
|Primary Investigator:||Meyerhardt, Jeffrey|
|Organization:||Dana-Farber Cancer Inst|
|Project Title:||The Influence of Diet and Lifestyle on Patients with Advanced Colorectal Cancer|
Project Summary/Abstract Epidemiologic and scientific research indicates that diet and other lifestyle factors have a significant influence on the risk of developing colorectal cancer. Emerging data suggest some of these factors impact on the outcomes of patients with early stage colon cancer. However, there are no data on the influence of diet, lifestyle and other host factors on the outcomes of patients with more advanced colorectal cancer. At the time of initial diagnosis, 20% of colorectal cancer patients have evidence of metastases and another 15- 20% will recur with metastatic disease within a few years of initial diagnosis. In the past 10 years, there have been substantial improvements in chemotherapy options for these patients, with median survival exceeding 2 years and increasing number of patients living 4 or more years. Patients often seek to understand what, if any, diet and lifestyle will improve their outcomes, both survival and tolerability of therapy. Moreover, how diet and lifestyle influence prognosis may depend, in part, on molecular characteristics of the tumor. In response to a NIH Program Announcement, PA-09-148, "Studies of Energy Balance and Cancer in Humans," we propose to address these gaps in knowledge by utilizing data from 2 National Cancer Institute-sponsored chemotherapy trials in newly diagnosed patients with stage IV colorectal cancer (CALGB 80203 and 80405) which provide a) prospective assessments of diet, medication, lifestyle and comorbidities; b) paraffin-embedded tumor specimens to examine how such factors interact with specific molecular alterations; c) blood samples for research purposes; and d) comprehensive data on cancer progression, mortality, and chemotherapy-related toxicity. Since stage, performance status, use of combination chemotherapy and follow-up were carefully defined in this trial, residual confounding by disease characteristics and use of chemotherapy should be minimized. This database will provide the unique opportunity to examine the influence of energy balance (Aim 1), diet and vitamin D (Aim 2) and aspirin/NSAIDs (Aim 3) on the outcomes of patients with advanced colorectal cancer. Beyond the aforementioned hypotheses, this cohort will allow for the rapid examination of future hypotheses as they emerge. Ultimately, this database will permit us to ascertain the influence of numerous factors on colorectal cancer survival, improve our understanding of colorectal cancer biology, and potentially offer substantive diet and lifestyle recommendations for patients and health care providers.
CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal cancer.
Authors: Rosenthal MH, Kim KW, Fuchs CS, Meyerhardt JA, Ramaiya NH
Source: Abdom Imaging, 2014 Oct 18;null, p. null.
EPub date: 2014 Oct 18.
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
Authors: Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA
Source: PLoS One, 2014;9(6), p. e99816.
EPub date: 2014 Jun 17.
Can we change the past for colorectal cancer patients and how do we move forward?
Authors: Jeon JY, Meyerhardt JA
Source: Cancer, 2014 May 15;120(10), p. 1450-2.
EPub date: 2014 Mar 3.
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Authors: Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, Alliance for Clinical Trials in Oncology
Source: J Natl Cancer Inst, 2013 Dec 4;105(23), p. 1789-98.
EPub date: 2013 Nov 14.
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
Authors: Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA
Source: Clin Colorectal Cancer, 2013 Dec;12(4), p. 233-8.
EPub date: 2013 Sep 10.
Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with ?-catenin (CTNNB1) status.
Authors: Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, Imamura Y, Liao X, Qian ZR, Ng K, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S
Source: Cancer Res, 2013 Mar 1;73(5), p. 1600-10.
EPub date: 2013 Feb 26.
Impact of diabetes on oncologic outcome of colorectal cancer patients: colon vs. rectal cancer.
Authors: Jeon JY, Jeong DH, Park MG, Lee JW, Chu SH, Park JH, Lee MK, Sato K, Ligibel JA, Meyerhardt JA, Kim NK
Source: PLoS One, 2013;8(2), p. e55196.
EPub date: 2013 Feb 6.
Prediagnostic plasma vitamin B6 (pyridoxal 5'-phosphate) and survival in patients with colorectal cancer.
Authors: Je Y, Lee JE, Ma J, Zhang X, Cho E, Rosner B, Selhub J, Fuchs CS, Meyerhardt J, Giovannucci E
Source: Cancer Causes Control, 2013 Apr;24(4), p. 719-29.
EPub date: 2013 Jan 23.
Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.
Authors: Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA
Source: Clin Colorectal Cancer, 2013 Jun;12(2), p. 95-102.
EPub date: 2013 Jan 12.
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.
Authors: Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E
Source: Mod Pathol, 2013 Apr;26(4), p. 465-84.
EPub date: 2013 Jan 11.
Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level.
Authors: Ogino S, Nishihara R, Lochhead P, Imamura Y, Kuchiba A, Morikawa T, Yamauchi M, Liao X, Qian ZR, Sun R, Sato K, Kirkner GJ, Wang M, Spiegelman D, Meyerhardt JA, Schernhammer ES, Chan AT, Giovannucci E, Fuchs CS
Source: J Natl Cancer Inst, 2013 Jan 16;105(2), p. 130-40.
EPub date: 2012 Nov 21.
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Authors: Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS
Source: J Natl Cancer Inst, 2012 Nov 21;104(22), p. 1702-11.
EPub date: 2012 Nov 7.
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Authors: Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S
Source: N Engl J Med, 2012 Oct 25;367(17), p. 1596-606.
Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.
Authors: Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, Fuchs CS, Ogino S
Source: Eur J Cancer, 2012 Dec;48(18), p. 3405-13.
EPub date: 2012 Jul 26.
Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
Authors: Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S
Source: Clin Cancer Res, 2012 Sep 1;18(17), p. 4753-63.
EPub date: 2012 Jul 2.
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
Authors: Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S
Source: Clin Cancer Res, 2012 Apr 15;18(8), p. 2257-68.
EPub date: 2012 Feb 22.
Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study.
Authors: Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S
Source: J Natl Cancer Inst, 2012 Mar 7;104(5), p. 415-20.
EPub date: 2012 Feb 6.
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Authors: Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D
Source: J Natl Cancer Inst, 2012 Feb 8;104(3), p. 211-27.
EPub date: 2012 Jan 20.
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
Authors: Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW
Source: Oncologist, 2012;17(1), p. 14.
EPub date: 2011 Dec 30.
Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer.
Authors: Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S
Source: Ann Surg Oncol, 2012 Jun;19(6), p. 1944-53.
EPub date: 2011 Dec 22.